| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H15NO4.ClH |
| Molecular Weight | 309.745 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.OC1=CC=C(C=C1O)[C@@H]2CNCC3=C2C=CC(O)=C3O
InChI
InChIKey=NHCWZEQEFHNLBQ-PPHPATTJSA-N
InChI=1S/C15H15NO4.ClH/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20;/h1-5,10,16-20H,6-7H2;1H/t10-;/m0./s1
YM-435 is a dopamine D1 agonist. The renal and cardiovascular effects of YM-435 may be suitable for the treatment of patients with renal insufficiency, heart failure and hypertension. It has been in phase II clinical trials for the treatment of heart failure and hypertension. YM435 may be useful in the preservation of renal function in ischemia-induced acute renal failure. Also, it might be a useful as therapeutic agent for the treatment of congestive heart failure.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
YM-435 displayed a capacity to promote cAMP formation in bovine retina when ATP/GppNHp was present. The maximally stimulated level of CAMP induced by YM 435 (210% of the controls; ATP/GppNHp only, no agonist added), was attained with 10 uM agonist. The EC50 value of YM-435-induced cAMP formation was 1.97 uM.
ACTIVE MOIETY
SUBSTANCE RECORD
